Related coverage linked through entity extraction aliases.
Jun 13, 2026
The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
Jun 07, 2026
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
Jun 05, 2026
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
May 22, 2026
Delaware's state employee health plan may raise GLP-1 copays from $32 to $120 per month or eliminate weight-loss drug coverage entirely, as costs are projected to reach $211 million by 2029. A decision is expected February 23, 2027.
May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Apr 25, 2026
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Apr 09, 2026
Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.
Apr 02, 2026
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
Apr 01, 2026
The FDA has shifted from regulatory ambiguity to coordinated enforcement against compounded oral semaglutide, culminating in a 2026 announcement of intent to take action against non-approved GLP-1 drugs. Hims & Hers Health's 2024 oral semaglutide offering marked the beginning of a broader regulatory reckoning that saw manufacturer pressure, formal shortage declarations, and warning letters targeting compounding practices.
Apr 01, 2026
The FDA has approved Eli Lilly's GLP-1 weight loss pill Foundayo, which will compete with Novo Nordisk's Wegovy pill. Foundayo will be available through LillyDirect and pharmacies, with prices ranging from $25 with insurance to $149-$349 for cash payers. The approval sets up a new battle in the oral GLP-1 market between the two pharmaceutical giants.
Mar 26, 2026
The European Union has approved a higher 7.2 mg maintenance dose for Wegovy (semaglutide) for chronic weight management. Clinical trial data shows mean weight loss of 20-21% with the 7.2 mg dose compared to 17-18% with the standard 2.4 mg dose. The approval provides clinicians with an on-label option for patients with inadequate response to standard dosing.
Mar 24, 2026
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
Mar 17, 2026
Over 25 companies are developing 30+ therapies for celiac disease, with recent positive trial results and FDA Fast Track designation. A new blood test using T-cell receptor sequencing may enable noninvasive diagnosis and monitoring.
Mar 11, 2026
Ascletis Pharma announced positive Phase II results for subcutaneous ASC30 showing 6.3% placebo-adjusted weight loss at 12 weeks, while advancing oral amylin receptor agonist ASC36 toward US FDA IND submission for obesity treatment.
Mar 06, 2026
Genentech announced positive Phase II results for petrelintide, showing up to 10.7% mean weight loss versus 1.7% placebo at week 42 in people with overweight and obesity, with placebo-like tolerability.
Mar 02, 2026
A new Cochrane review analyzing 22 randomized clinical trials involving 1,995 adults found intermittent fasting produces no clinically meaningful weight loss compared to traditional dietary advice or no intervention.
Feb 27, 2026
The FDA announced plans to restrict GLP-1 active pharmaceutical ingredients for compounded drugs and combat misleading advertising, following the Trump administration's launch of TrumpRx and ongoing enforcement actions against compounding pharmacies.
Feb 20, 2026
The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing physicians with an additional treatment option for patients requiring further weight reduction after the 2.4 mg dose.
Feb 25, 2026
Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.
